Staging metastatic urothelial cancer with Nectin‐4 imaging using Gallium‐68‐ N188 PET / CT
BJU International · 2026-01 · 137 (1) · 166-172
DOI: 10.1111/bju.16901 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, online erschienen am 23.08.2025. Verfasst von Matthias Miederer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Imaging in Oncology, National Center for Tumor Diseases (NCT), NCT/UCC Dresden, a partnership between DKFZ, Faculty of Me…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Cell Adhesion Molecules, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To quantify Nectin‐4 expression in tumour lesions using the Nectin‐4‐binding peptide Gallium‐68‐N188 and positron emission tomography (PET)/computed tomography (CT) in patients with advanced or metastasised urothelial cancer eligible for therapy with the Nectin‐4‐directed antibody–drug conjugate enfortumab vedotin, in combination with checkpoint inhibitor pembrolizumab (Ev/P).
Methods
In 10 patients, Nectin‐4 PET/CT imaging was analysed before planned systemic therapy with Ev/P based on standardised uptake value (SUV) measurements and the results were correlated to available microscopic findings on Nectin‐4 immunohistochemistry and to clinical follow‐up.
Results
Nectin‐4 PET is suitable for detecting Nectin‐4 expression in tumour lesions and demonstrates heterogeneity in Nectin‐4 expression – for example, between lymph node metastases and organ metastases. PET imaging of Nectin‐4 expression is therefore a potentially clinically relevant method for managing the application of Nectin‐4‐targeted therapies.
Conclusions
We show, as a proof of principle, that Nectin‐4 expression can be detected on imaging and serves as an innovative biomarker for targeted therapy in urothelial cancer. Intra‐individual heterogeneous expression of Nectin‐4 in metastatic sites is frequent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Imaging in Oncology, National Center for Tumor Diseases (NCT), NCT/UCC Dresden, a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden Universi…
- Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
- Department of Urology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
- Department of Pathology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
ORCID-Profile: Matthias Miederer, Joana do Mar Ferreira Machado
Zitieren
APA
Miederer, M., Pretze, M., Abbate, E., Hartig, A., do Mar Ferreira Machado, J., Böhm, K., Sommer, U., Hoberück, S., Bundschuh, R. A., Kotzerke, J., & Thomas, C. (2026). Staging metastatic urothelial cancer with Nectin‐4 imaging using Gallium‐68‐ N188 PET / CT. BJU International, 137(1), 166-172. https://doi.org/10.1111/bju.16901
Vancouver
Miederer M, Pretze M, Abbate E, Hartig A, do Mar Ferreira Machado J, Böhm K, et al. Staging metastatic urothelial cancer with Nectin‐4 imaging using Gallium‐68‐ N188 PET / CT. BJU International. 2026;137(1):166-172. doi:10.1111/bju.16901
BibTeX
@article{Miederer2026,
author = {Miederer, Matthias and Pretze, Marc and Abbate, Elena and Hartig, Andreas and do Mar Ferreira Machado, Joana and Böhm, Katharina and Sommer, Ulrich and Hoberück, Sebastian and Bundschuh, Ralph A and Kotzerke, Jörg and Thomas, Christian},
title = {Staging metastatic urothelial cancer with Nectin‐4 imaging using Gallium‐68‐ N188 PET / CT},
journal = {BJU International},
year = {2026},
volume = {137},
number = {1},
pages = {166--172},
doi = {10.1111/bju.16901}
}
EUVIMED